Aranesp (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney disease (CKD) in both dialysis and non-dialysis patients, as well as for patients undergoing myelosuppressive chemotherapy. The recommended starting doses vary depending on the patient's situation, with specific dosing guidelines provided for different groups. Aranesp is contraindicated in patients with uncontrolled hypertension, pure red cell aplasia after treatment, and serious allergic reactions.

1. ARANESP :
DARBEPOETIN ALFA
‫السريرية‬ ‫الصيدالنية‬ ‫اعداد‬
‫الدين‬ ‫بدر‬ ‫محمد‬ ‫رؤى‬

2. Indications and Usage
Treatment of anemia due to:
• Chronic Kidney Disease (CKD) in patients on dialysis and
patients not on dialysis.
• The effects of concomitant myelosuppressive
chemotherapy, and upon initiation, there is a minimum of
two additional months of planned chemotherapy.

3. Aranesp Dosage and Administration
• Recommended starting dose for patients with CKD on
dialysis:
- 0.45 mcg/kg intravenously or subcutaneously weekly, or
- 0.75 mcg/kg intravenously or subcutaneously every 2
weeks
- Intravenous route is recommended for patients on
hemodialysis
• Recommended starting dose for patients with CKD not on
dialysis:
- 0.45 mcg/kg intravenously or subcutaneously at 4 week
intervals.

6. Contraindications
Aranesp is contraindicated in patients with:
• Uncontrolled hypertension.
• Pure red cell aplasia (PRCA) that begins after treatment
with Aranesp or other erythropoietin protein drugs.
• Serious allergic reactions to Aranesp.